EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint, Inc., a clinical-stage biopharmaceutical company focusing on retinal disease treatments, announced inducement stock option grants to fourteen new employees totaling 362,500 shares. These grants comply with NASDAQ Listing Rule 5635(c)(4) and are intended as incentives for recruitment. The company's lead candidate, DURAVYU™, is currently in…